ACE and hydrops fetalis: A new era of neuroendocrine inhibitor treatment for HF began in 1987, when CONSENSUS successfully confirmed that treatment with angiotensin-converting enzyme inhibitors reduced the mortality rate in patients with HF by 27% [6].